Table 2.
Summary of recurrent genetic lesions in T-ALL
| Gene(s) involved | Functional consequences | Frequency |
Clinical relevance | ||
|---|---|---|---|---|---|
| children | adults | ||||
| Translocation of TCR with various oncogenes | LMO1, LMO2, TAL1, TLX1, and TLX3 | Hemopoiesis deregulation, impairment of differentiation | ~35% | No impact | |
| Del(1)(p32) | SIL-TAL1 | Impairment of differentiation | ~10% | 5 – 10% | Not clearly established |
| 9p deletion | CDKN2A and CDKN2B | Loss of cell proliferation control | 20 – 30% | <1% | No impact |
| 11q23 rearrangements | MLL with various partners | Disruption of HOX gene expression and the self-renewal properties of hemopoietic progenitors | ~5% | Poor outcome | |
| t(9;9)(q34;q34) | NUP214-ABL | ABL constitutive activation | 6% | No impact | |
| t(9;14)(q34;q32) | EML1-ABL | ABL constitutive activation | 1% | No impact | |